| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 183 |
| 1 | ENFORTUMAB VEDOTIN | 126 |
| 2 | IPILIMUMAB | 121 |
| 3 | CARBOPLATIN | 111 |
| 4 | BEVACIZUMAB | 86 |
| 5 | PACLITAXEL | 78 |
| 6 | PEMETREXED DISODIUM | 58 |
| 7 | DURVALUMAB | 57 |
| 8 | TACROLIMUS | 37 |
| 9 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 35 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ENFORTUMAB VEDOTIN | 126 | 0.0160 |
| 1 | ONTRUZANT | 8 | 0.0153 |
| 2 | CROVALIMAB | 1 | 0.0083 |
| 3 | PLATINUM | 4 | 0.0075 |
| 4 | TREMELIMUMAB | 24 | 0.0054 |
| 5 | TEBENTAFUSP | 3 | 0.0050 |
| 6 | TALIMOGENE LAHERPAREPVEC | 7 | 0.0044 |
| 7 | CEMIPLIMAB-RWLC | 8 | 0.0038 |
| 8 | IPILIMUMAB | 121 | 0.0028 |
| 9 | DURVALUMAB | 57 | 0.0026 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Complement C5 Inhibitor [EPC] | 1 | 0.0083 |
| 1 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 3 | 0.0050 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 144 | 0.0030 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 57 | 0.0026 |
| 4 | Lymphocyte Activation Gene-3 Blocker [EPC] | 1 | 0.0019 |
| 5 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 184 | 0.0019 |
| 6 | Lymphocyte Growth Factor [EPC] | 1 | 0.0008 |
| 7 | Platinum-based Drug [EPC] | 157 | 0.0006 |
| 8 | Microtubule Inhibitor [EPC] | 93 | 0.0006 |
| 9 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 94 | 0.0005 |